Pantherna plans to partner its in-house development programs at the pre-clinical or clinical stage.

We focus on patients with an Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition associated with viral and bacterial lung infections.

In addition, we are interested in research collaborations and pre-clinical development agreements with industry partners to extend the applications of Pantherna’s proprietary lipid nanoparticle mRNA expression technology platforms (PTX_LNP™, PTXmRNA™).

We are open to research agreements with academia and biotech that have complementary research interest and corresponding capabilities in selected indications proposed by the respective partner.